全球神经再生疗法市场

预计到 2030 年全球神经再生疗法市场规模将达到 472 亿美元

全球神经再生疗法市场规模在 2024 年估计为 378 亿美元，预计到 2030 年将达到 472 亿美元，在 2024-2030 年分析期内的复合年增长率为 3.8%。 N-甲基-D-天门冬胺酸受体拮抗剂是报告中分析的细分市场之一，预计复合年增长率为 4.0%，到分析期结束时将达到 179 亿美元。在分析期内，胆碱酯酶抑制剂部分预计将以 2.8% 的复合年增长率成长。

美国市场规模估计为 103 亿美元，中国市场预计复合年增长率为 7.0%

预计2024年美国神经再生治疗市场规模将达103亿美元。作为世界第二大经济体的中国，预计2030年市场规模将达到95亿美元，在2024-2030年分析期间的复合年增长率为7.0%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 1.5% 和 2.9%。在欧洲，德国的复合年增长率预计为 2.2%。

全球神经再生疗法市场—主要趋势与驱动因素摘要

为什么神经再生疗法在治疗中枢神经系统和周边神经系统损伤方面在全球范围内越来越受到青睐？

神经再生治疗已成为神经科学和再生医学的前沿领域，为中枢和周围神经系统损伤患者带来了希望。创伤、中风、神经退化性疾病和去髓鞘化等造成的神经损伤传统上被认为是不可逆的，现在正成为介入治疗的目标，以促进轴突再生、突触重建、髓鞘再生和功能恢復。这种从症状治疗到实际神经组织修復的模式转移正在彻底改变神经康復，并将神经再生定位为神经治疗未来基石。

全球范围内脊髓损伤、多发性硬化症、帕金森氏症、阿兹海默症和创伤性脑损伤发病率的不断上升推动了对神经再生疗法的需求。由于人口老化以及道路交通事故和运动伤害的增加，患有衰弱性神经病变的人数不断增加。传统治疗方法只能提供有限的康復机会，并且主要侧重于减缓疾病的进展。相较之下，神经再生疗法旨在恢復失去的功能，从而产生了新一代的治疗策略，这些策略是治癒性的而不是缓解性的。

干细胞、生长因子和基因疗法等新治疗方法将如何改变神经再生？

神经再生疗法的技术核心围绕着尖端生技药品和工程细胞系统。干细胞疗法，特别是间质干细胞（MSC）、诱导性多功能干细胞（iPSC）和神经前驱细胞，是临床开发中最前线的方法之一。这些细胞分泌神经营养因子，调节炎症，并分化为有助于修復受损神经组织的神经元样细胞。临床试验正在研究其在脊髓损伤、中风復健、肌萎缩侧索硬化症、多发性硬化症等领域的应用，早期结果令人鼓舞。

生长因子疗法，包括脑源性神经营养因子 (BDNF)、神经胶质细胞株源性神经营养因子 (GDNF) 和睫状神经营养因子 (CNTF)，已透过病毒载体、生医材料或直接注射进行给药，以促进神经元存活和可塑性。针对神经发炎、髓鞘修復和突触功能障碍的基因疗法已显示出良好的前景，尤其是在遗传性神经退化性疾病。生医材料支架、水凝胶基质和神经介面的进步也使得在局部和永续地输送这些再生剂成为可能。这些技术进步正在重新定义治疗预期，强调神经恢復和电路重新整合，而不是简单的症状抑制。

哪些临床应用与病患群体正在塑造神经再生市场格局？

神经再生疗法正在广泛的临床应用中进行研究，包括脊髓损伤、创伤性脑损伤 (TBI)、週边神经损伤、缺血性中风、多发性硬化症以及 ALS 和帕金森氏症等神经退化性疾病。患有慢性神经损伤的患者，尤其是那些具有部分残留功能或处于退化早期阶段的患者，是目前再生疗法的最佳候选人。小儿神经病学，特别是脑性麻痹和神经管缺陷，也是未来治疗创新的目标。

北美、欧洲和亚太等神经创伤、中风和老龄化相关性神经退化发生率较高的地区正在推动临床试验活动和市场需求。美国在监管发展和干细胞临床基础设施方面处于领先地位，而日本和韩国正在有利的管理体制下推动再生医学临床试验。拉丁美洲和中东的新兴市场正在投资发展康復基础设施并参与国际临床试验，以便更广泛地获得实验性再生疗法。患者对参与临床试验的倡议和兴趣的增加进一步扩大了市场基础。

什么将推动神经再生疗法市场的长期成长和创新？

神经再生疗法市场的成长受到干细胞生物学、生物材料科学、分子神经生物学和精准基因编辑的融合所推动。对神经系统可塑性和刺激内源性修復机制的能力的认识正在改变神经损伤的临床治疗方法。先进治疗药物（ATMP）的法规结构正在完善，以加速再生神经疗法的开发和商业化。公共和私人对神经再生研究的投资正在成长，跨学科合作正在刺激创新。

临床检验、可扩展製造、道德采购和长期安全监测仍然是重大挑战。然而，随着早期试验数据的成熟和交付技术的日益复杂，预计将有越来越多的神经再生产品获得市场核准。数位神经復健工具、穿戴式神经刺激设备和远端患者监护系统的整合度提高将进一步加强对治疗依从性和结果的追踪。随着神经再生成为神经治疗的重要支柱，它很可能在恢復全球数百万人的功能和改善他们的生活品质方面发挥变革性的作用。

部分

药物类型（N-甲基-D-天冬胺酸受体拮抗剂、胆碱酯酶抑制剂、多巴胺促效剂、免疫调节剂、其他药物类型）、适应症类型（帕金森氏症适应症、阿兹海默症适应症、多发性硬化症适应症、其他适应症）、给药途径（口服途径、肠外途径、经皮症适应症、多发性硬化症适应症、其他适应症）、给药途径（口服途径、肠外途径、透皮症适应症、终端使用者（终端使用者（终端使用者）

受访公司范例（总合42家公司）

• Abbott Laboratories
• Acadia Pharmaceuticals Inc.
• Alector, Inc.
• Anavex Life Sciences Corp.
• Annovis Bio, Inc.
• AstraZeneca plc
• Biogen Inc.
• Boston Scientific Corporation
• Ceregene, Inc.
• Coave Therapeutics
• Denali Therapeutics Inc.
• Integra LifeSciences Holdings Corp.
• Medtronic plc
• Merck & Co., Inc.
• NeuExcell Therapeutics
• Neurona Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Polyganics BV
• Teva Pharmaceutical Industries Ltd.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口（成品和OEM）预测公司竞争地位的变化。这种复杂且多方面的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、降低盈利、重组供应链等微观和宏观市场动态。

全球产业分析师密切关注世界领先的首席经济学家（14,949）、智库（62）和贸易及产业协会（171）的专家意见，以评估生态系统的影响并应对新的市场现实。各主要国家的专家和经济学家都在关注关税及其对国家的影响。

全球产业分析师预计，这种动盪将在未来几个月内平息，新的世界秩序将更加明确地建立。全球产业分析师正在即时追踪这些发展。

2025年4月：谈判阶段

我们四月份的发布将涵盖关税对全球市场整体的影响，并为各地区的市场调整提供指导。我们的预测是基于历史数据和不断发展的市场影响因素。

2025年7月：最终关税调整

免费更新 在各国宣布最终重置后，本公司的客户将在 7 月收到免费更新。最终更新包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业和领域专家的最具影响力的首席经济学家，他们共用了全球经济状况这一前所未有的模式转移的影响。我们的 16,491 多份报告中的大多数都遵循这个基于两阶段里程碑的发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Neuroregeneration Therapy Market to Reach US$47.2 Billion by 2030

The global market for Neuroregeneration Therapy estimated at US$37.8 Billion in the year 2024, is expected to reach US$47.2 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. N-methyl-D-aspartate Receptor Antagonists, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.9 Billion by the end of the analysis period. Growth in the Cholinesterase Inhibitors segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.3 Billion While China is Forecast to Grow at 7.0% CAGR

The Neuroregeneration Therapy market in the U.S. is estimated at US$10.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.5 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Neuroregeneration Therapy Market - Key Trends & Drivers Summarized

Why Is Neuroregeneration Therapy Gaining Global Momentum in the Treatment of CNS and PNS Injuries?

Neuroregeneration therapy is emerging as a frontier area in neuroscience and regenerative medicine, offering hope for patients suffering from central and peripheral nervous system damage. Traditionally considered irreversible, neural injuries caused by trauma, stroke, neurodegenerative diseases, or demyelination are now being targeted with interventions that promote axonal regrowth, synaptic reformation, remyelination, and functional recovery. This paradigm shift from symptomatic management to actual nerve tissue repair is revolutionizing neurological rehabilitation and positioning neuroregeneration as a cornerstone of future neurotherapeutics.

The demand for neuroregeneration therapy is driven by the increasing global incidence of spinal cord injuries, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and traumatic brain injuries. With an aging population and rising road traffic accidents and sports-related traumas, the number of individuals suffering from debilitating neurological impairments continues to rise. Traditional therapies offer limited recovery potential and focus largely on slowing disease progression. In contrast, neuroregeneration therapies aim to restore lost function, giving rise to a new generation of curative, rather than palliative, treatment strategies.

How Are Emerging Modalities Like Stem Cells, Growth Factors, and Gene Therapies Transforming Neuroregeneration?

The technological core of neuroregeneration therapy revolves around cutting-edge biologics and engineered cell systems. Stem cell therapy-particularly mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural progenitor cells-is one of the most advanced approaches under clinical development. These cells secrete neurotrophic factors, modulate inflammation, and differentiate into neuron-like cells that aid in repairing damaged neural tissue. Clinical trials are exploring their use in spinal cord injuries, stroke recovery, ALS, and multiple sclerosis with promising early results.

Growth factor therapies-including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF)-are being delivered through viral vectors, biomaterials, or direct infusion to promote neuronal survival and plasticity. Gene therapies targeting neuroinflammation, myelin repair, or synaptic dysfunction are showing potential, especially in hereditary neurodegenerative diseases. Advances in biomaterial scaffolds, hydrogel matrices, and neural interfaces are also enabling localized, sustained delivery of these regenerative agents. These innovations are redefining therapeutic expectations, emphasizing neural restoration and circuit reintegration over mere symptom suppression.

Which Clinical Applications and Patient Populations Are Shaping the Neuroregeneration Market Landscape?

Neuroregeneration therapy is being investigated across a wide range of clinical applications, including spinal cord injuries, traumatic brain injuries (TBIs), peripheral nerve injuries, ischemic stroke, multiple sclerosis, and neurodegenerative diseases such as ALS and Parkinson’s. Patients with chronic neural damage-especially those with partial residual function or early-stage degeneration-are currently the best candidates for regenerative intervention. The pediatric neurology segment, particularly in cerebral palsy and congenital neural tube defects, is also a target for future therapeutic innovation.

Regions with high incidence of neurotrauma, stroke, and aging-related neurodegeneration-such as North America, Europe, and Asia-Pacific-are driving clinical trial activity and market demand. The U.S. leads in terms of regulatory progress and stem cell clinical infrastructure, while Japan and South Korea are advancing regenerative trials under favorable regulatory regimes. Emerging markets in Latin America and the Middle East are investing in rehabilitation infrastructure and international trial participation, enabling wider access to experimental regenerative therapies. Increasing patient advocacy and awareness of clinical trial participation are further broadening the market’s reach.

What Is Driving Long-Term Growth and Innovation in the Neuroregeneration Therapy Market?

The growth in the neuroregeneration therapy market is driven by the convergence of stem cell biology, biomaterials science, molecular neurobiology, and precision gene editing. The recognition of the nervous system’s plasticity and the ability to stimulate endogenous repair mechanisms is shifting the clinical approach to neural injuries. Regulatory frameworks for advanced therapy medicinal products (ATMPs) are being refined to accelerate the development and commercialization of regenerative neurotherapies. Public and private investment in neurorestorative research is expanding, with cross-disciplinary collaboration fueling innovation.

Clinical validation, scalable manufacturing, ethical sourcing, and long-term safety monitoring remain critical challenges. However, as data from early-phase trials mature, and as delivery technologies become more refined, a growing number of neuroregeneration products are expected to reach market approval. The increasing integration of digital neurorehabilitation tools, wearable neurostimulation devices, and remote patient monitoring systems will further enhance treatment adherence and outcome tracking. As neuroregeneration becomes a key pillar of neurotherapeutics, it will play a transformative role in improving functional recovery and quality of life for millions worldwide.

SCOPE OF STUDY:

The report analyzes the Neuroregeneration Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Other Drug Types); Indication Type (Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication, Other Indications); Administration Route (Oral Route, Parenteral Route, Transdermal Route); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online Pharmacies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Acadia Pharmaceuticals Inc.
• Alector, Inc.
• Anavex Life Sciences Corp.
• Annovis Bio, Inc.
• AstraZeneca plc
• Biogen Inc.
• Boston Scientific Corporation
• Ceregene, Inc.
• Coave Therapeutics
• Denali Therapeutics Inc.
• Integra LifeSciences Holdings Corp.
• Medtronic plc
• Merck & Co., Inc.
• NeuExcell Therapeutics
• Neurona Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Polyganics B.V.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Neuroregeneration Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Understanding of CNS Plasticity Mechanisms Spurs Innovation in Neuroregeneration Therapies
  • Increased Incidence of Spinal Cord Injury and Stroke Expands Addressable Market for Regenerative Interventions
  • Emergence of Stem Cell and iPSC-Based Approaches Propels Growth in Cell Therapy Pipelines
  • Rising Investment in Neurotrophic Factor Research Enhances Drug Discovery Potential
  • Availability of Gene Therapy Vectors Strengthens Business Case for Precision Regeneration
  • Advances in Bioactive Scaffolds and Hydrogels Accelerate Adoption of Tissue Engineering Solutions
  • Integration of Electrical Stimulation Techniques Drives Synaptic Recovery and Functional Restoration
  • Global Increase in Neurotrauma-Linked Disabilities Sustains Demand for Regenerative Solutions
  • Adoption of 3D Bioprinting for Neural Tissue Constructs Throws the Spotlight on Personalized Regeneration
  • Expansion of Academic-Industry Collaborations Spurs Translational Neuroregeneration Research
  • Improved Preclinical Models Enhance Efficacy Validation in Early-Stage Drug Development
  • Rising Regulatory Support for Regenerative Medicines Drives Clinical Trial Approvals
  • Integration of AI in Cell Therapy Manufacturing Optimizes Scalability and Quality Control
  • Growing Availability of Companion Diagnostics Enhances Therapy Precision and Targeting
  • Limited Efficacy of Current Neurorestorative Therapies Strengthens Demand for Breakthrough Solutions
  • Public-Private Investments in Brain Injury Recovery Programs Accelerate Product Commercialization
  • Development of Nanocarrier-Based Delivery Systems Supports Efficient Neurotrophic Transport
  • Growing Pipeline for ALS, MS, and Parkinson's Disease Drives Diversified Applications
  • Complexities in Long-Term Efficacy and Safety Tracking Pose Clinical Trial Design Challenges
  • Increased Reimbursement Coverage for Cell-Based Therapies Expands Patient Accessibility
  • Technological Advancements in Live Imaging and CNS Mapping Facilitate Outcome Monitoring
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neuroregeneration Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neuroregeneration Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Transdermal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Transdermal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Transdermal Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Parkinson's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Parkinson's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Parkinson's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Alzheimer's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Neuroregeneration Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Neuroregeneration Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Neuroregeneration Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Neuroregeneration Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION